- Price
- $19.55
- Day
- +2.84%
- Mkt Cap
- $37.54B
- 52W Range
- $14.02 – $22.22
- Volume
- 15.90M
- Beta
- 0.44
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
KVUE is expected to post Q2 revenue and earnings growth as brand strength, innovation and productivity efforts offset seasonal and cost pressures.
Read full article
SUMMIT, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) today announced that its Board of Directors declared a quarterly dividend of $0.21 per share on its common stock, which represents a 1.2 percent increase compared to the prior quarterly dividend. The quarterly dividend is payable on August 26, 2026, to shareholders of record as of the close of business on August 12, 2026. About Kenvue Kenvue Inc. is the world's largest pure-play consumer health company by revenue. Built on more than a cent.
Read full article
Kenvue's beauty momentum, margin expansion and stronger cash flow support its outlook as uneven demand and deal uncertainty temper visibility.
Read full article
KVUE's margin gains and stronger cash flow boost its appeal, but slow organic growth, debt and deal uncertainty keep the outlook balanced.
Read full article
KVUE's trusted brands, margin gains and pending Kimberly-Clark deal shape its outlook amid mixed growth signals.
Read full article
Black Monday was on Monday, October 19, 1987, almost 40 years ago, and market veterans and long-time investors usually mention one important item: nobody really saw it coming or expected it.
Read full article
Gabelli Funds LLC increased its stake in Kenvue Inc. (NYSE: KVUE) by 71.2% during the undefined quarter, according to its most recent Form 13F filing with the SEC. The fund owned 724,635 shares of the company's stock after acquiring an additional 301,350 shares during the period. Gabelli Funds LLC's holdings in Kenvue were
Read full article
Kenvue Inc. (NYSE: KVUE - Get Free Report) has been given an average recommendation of "Hold" by the sixteen research firms that are covering the firm, MarketBeat.com reports. Thirteen equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average 1 year price target
Read full article
The U.S. Food and Drug Administration on Friday approved a nonprescription, fixed-dose pill that combines Kenvue's Tylenol with the nonsteroidal anti-inflammatory drug naproxen for up to 12 hours of pain relief.
Read full article
SUMMIT, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) will announce its second quarter 2026 financial results before the market opens on August 6, 2026. Due to the pending transaction with Kimberly-Clark, Kenvue will not be hosting a quarterly conference call to review its financial results. The press release will be available on the company's website at investors.kenvue.com. About Kenvue Kenvue Inc. is the world's largest pure-play consumer health company by revenue. Built on more than a cen.
Read full article
This Dividend King just made a major strategic pivot.
Read full article